Abstract
Chimeric antigen receptor (CAR) T-cell therapy has become a factible therapy for hematologic neoplasms. Prior to infusion, strategies as lymphodepletion and bridge therapy are frequently performed to prolong the persistence of infused cells and increase the effectiveness of the treatment. The aim of this review is to investigate the use of Lymphodepletion and bridge therapy, protocols available, indications, advantages, negative effects, agent associated toxicity, applicability for specific onco-hematological diseases and how to optimize the procedure, guarantying security and efficacy of this approach.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
